Epstein-Barr virus (EBV)-genome-negative human lymphoma lines, Ramos and BJAB, can be converted by EBV in vitro into EBV-genome-positive virus nonproducer lines. These cell lines have been used to identify surface antigens unique to EBV, with the expectation that such determinants might be related to the antigenic target responsible for EBV-specific immunosurveillance. Antisera prepared in rabbits immunized with either whole cells or purified plasma membranes were used in immunoblot experiments to analyze antigenic differences resulting from expression of the resident EBV genome. Unexpectedly, an increase in polypeptides of 32 and 70 kilodaltons was consistently observed in the EBV-converted Ramos lines. In contrast, these antigens were not expressed in BJAB or in its EBV-converted lines. These data suggested that p32 and gp7O might be murine leukemia virus (MuLV)-coded antigens because Ramos, but not BJAB, had been passaged in athymic nude mice during establishment of this cell line. This conclusion was confirmed by using antisera specific for MuLV p30 and gp7O. Retroviral antigens were expressed constitutively at low levels in Ramos. Quantitative immunoblotting showed that EBV conversion of Ramos amplified the expression of MuLV proteins 3to 5-fold. The molecular mechanism responsible for the enhanced expression is unknown. The biological relevance of this phenomenon is also not clear, but the interaction between a DNA and a RNA tumor virus in a Burkitt lymphoma line that carries both viruses may have important biological consequences in relation to retrovirus latency and tumor induction. These results also show
that caution must be used when ascribing "uniqueness" to EBV-determined antigens, particularly in the Ramos lines. This warning extends also to the use of Ramos cell lines as immunogens, because immunization of rabbits elicited antibodies that recognized proteins of the same size as the retroviral antigens.
Epstein-Barr virus (EBV), a B-lymphocyte tropic virus of human and some nonhuman primates, is responsible for infectious mononucleosis and is associated with two human malignancies, Burkitt lymphoma (BL) and nasopharyngeal carcinoma (NPC) (1) . Several EBV-converted virus nonproducer lines derived by in vitro transformation of two EBVnegative BL lines, Ramos and BJAB, are available for study. Conversion leads to many biological changes that are analogous to those resulting from transformation of fibroblasts by known tumor viruses-e.g., simian virus 40, polyoma virus, and Rous sarcoma virus (2) . The converted lines differ depending on which of the two EBV strains, P3HR-1 or B95-8, is used for conversion (3) . Comparison of subline pairs derived from the same original monoclonal tumor cell population minimizes the study of trivial subline differences and allows one to examine the biochemical characteristics where the sublines differ.
A major objective of our studies has been to identify antigens unique to the surface of EBV-converted virus nonproducing cells to define the antigenic target recognized by the host immune system. Such a target must exist and is likely responsible for the effective immunosurveillance against this virus of high transforming potential. For cells transformed by ubiquitous oncogenic viruses, the rejection targets on the outer cell surface appear to be virally induced proteins and not virion proteins (4) . In fact, the EBV-producing cells are not detected in BL or NPC tumors, even though 97% of the cells carry the EBV genome (5) . The viral proteins appear to be important, however, as targets for antibody-dependent and killer-cell-mediated cytotoxic mechanisms that destroy virus-producing cells that enter the lytic cycle (4) .
In the present study, EBV-related differences were identified by immunoblotting methods using antiserum prepared in rabbits against the EBV-negative and converted lines. During the course of these studies, we observed an enhanced expression in the EBV-converted Ramos lines of proteins with molecular weights expected for the retroviral antigens, p30, p65, and gp7O. Evidence is presented in this paper to show that EBV conversion of Ramos amplifies expression of the proviral murine leukemia virus (MuLV) antigens. Ramos presumably acquired the MuLV provirus when it was passaged in athymic nude mice during establishment of the cell line in culture (6) . BJAB was not passaged in nude mice and therefore does not express MuLV gene products. Although there is little evidence to suggest the involvement of a retrovirus in EBV transformation, these results may be of potential interest because insertional activation of retroviral genes by EBV could be an important mechanism of retroviral tumor induction. Using DNA restriction mapping analyses, we are currently trying to determine whether enhanced expression occurs directly by insertion of promoter or enhancer regions of EBV.
EXPERIMENTAL PROCEDURES
Cell Lines and Growth Conditions. Properties of the lymphoma cell lines used in this study are summarized in Table  1 . All cell lines were generously supplied by George Klein of the Karolinska Institute (Stockholm, Sweden). The BJAB/B-1 subline was a P3HR-1 convertant that was kindly supplied by George Miller (Yale University School of Medicine). The Ramos line was established from an EBVgenome-negative American BL, and, during establishment of this line, it was passaged in nude mice (6) . BJAB, also a B-Abbreviations: EBV, Epstein-Barr virus; BL, Burkitt lymphoma; NPC, nasopharyngeal carcinoma; MuLV, murine leukemia virus; kDa, kilodalton(s); P,/NaCI, phosphate-buffered saline.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (7) B95-8 BJAB/B95-8 1 (9), 19 (11) B95-8 All cell lines were derived from BL. cell lymphoma line, was established from an EBV-genomenegative African BL case (12) . Ramos and BJAB both lack the EBV genome and therefore do not express the EBV-related antigens: nuclear antigen, early antigen, viral capsid antigen, or membrane antigen. Both Ramos and BJAB are sensitive to EBV infection in vitro by either of two EBV strains, P3HR-1 or B95-8 (12) . These studies have used EBV-converted virus-nonproducing lines that are nuclear antigen positive but early antigen, viral capsid antigen, and membrane antigen negative. As summarized in Table 1 (13) . The plasma membrane fraction sedimented by centrifugation at 95,000 x g for 90 min was used without further purification. Membranes were suspended in 0.20-0.30 ml of lysis buffer (10 mM Tris HCI, pH 7.4/1.0 mM MgCI2/1.0 mM CaCI2). The protein concentration of the membranes was determined and an appropriate dilution into the NaDodSO4 sample buffer was made, as described below.
Isolation of Cell Antigens by Triton X-100 Extraction. Antigens were extracted from the lymphoid cells by Triton X-100 as described (14) . The extraction buffer was supplemented with 1 mM phenylmethylsulfonyl fluoride/leupeptin (1 g/ml)/ DNase (50 g/ml)/RNase (50 g/ml). The detergent extract was diluted with twice-concentrated sample buffer to achieve final concentrations of 62.5 mM Tris.HCI/2% NaDodSO4/5% 2-mercaptoethanol/10% glycerol/0.001% bromphenol blue, pH 6.8. Proteins were further diluted with sample buffer, when necessary, to achieve a NaDodSO4/ protein ratio of 4:1 (wt/wt). Samples were heated at 90°C for 5-10 min and stored at -20°C. NaDodSO4/Polyacrylamide Gel Electrophoresis. The discontinuous buffer system of Laemmli was used (15) . Gradient gels with a range of 7.5% to 15% acrylamide (top to bottom) were used with 4% acrylamide stacking gel. Ninety micrograms of Triton X-100-solubilized protein in NaDodSO4 was loaded into each sample well. Highand low-range molecular weight standards were obtained from Pharmacia and prepared according to the manufacturer's instructions.
Electrophoresis was carried out with a Hoeffer no. 520 vertical slab gel apparatus cooled to 4°C with circulating antifreeze. During stacking, the voltage was set at 100 V for 4 hr. The voltage was then increased to 150 V for 18 hr. Electrophoresis was stopped when the dye front had migrated 18-20 cm from the top of the resolving gel.
Electrotransfer of Proteins. Electrophoretic transfer of proteins onto nitrocellulose sheets was done by the method of Towbin et al. (16) with an electrode buffer of 25 mM Tris-HCl, pH 8.3/192 mM glycine/20% (vol/vol) methanol. Electroblotting was carried out at 200 mA for a minimum of 6 hr. After blotting, the portion of the nitrocellulose containing the molecular weight standards was cut off, stained for 10 min with 0.1% amido black in destaining solution, and then destained in 45% (vol/vol) methanol/45% water/10% acetic acid.
Immunological Detection (Immunoblotting) of Antigens on Nitrocellulose. After removal of the molecular weight standard lane, the nitrocellulose blots were incubated in 3% bovine serum albumin/0.9% NaCI/10 mM Tris-HC, pH 7.4, for 1 hr. Blots were then washed three times with phosphatebuffered saline (Pi/NaCI) for a minimum total time of 30 min.
The blots were then incubated in an appropriate dilution (usually 1:50 or 1:100) of the antiserum of interest in serum dilution buffer (0.15 M NaCl/1 mM Na4 EDTA/50 mM Tris-HCI/0.02% sodium azide/0.1% bovine serum albumin/0.05% Tween 20, pH 7.4) for a minimum of 3 hr. The unbound antibodies were removed by washing three times with P1/NaCl using three changes over 30 min. The bound antibodies from the primary antiserum were detected by incubating the blot with a radioiodinated antibody against IgG molecules from the species of the primary antiserum. For detection of goat anti-p30, 47,000 dpm per ml of 125I-labeled rabbit antibody to goat IgG was used. Blots were incubated with the labeled second antibodies for ca. 3 hr. Unbound antibodies were removed by washing five times with Pi/ NaCl. Immunoblots were then dried and placed on Kodak XAR-2 film for autoradiography.
Preparation of Antisera to EBV-Negative and Converted Cells. Antibodies against the lymphoma cells were made by initially injecting rabbits intravenously with 1 x 108 cells in Pi/NaCl. Two weeks later, a booster injection of 2 x 107 cells in Pi/NaCl was injected intravenously and subcutaneously. Titers were maintained by monthly subcutaneous injections of 2-4 x 107 cells homogenized in Freund's incomplete adjuvant. Antibody titer was determined by enzymelinked immunosorbent assay as described (17) . The titer of anti-AW-Ramos (designated a-803) used in these experiments was 1:16,000.
Affinity-purified rabbit anti-goat IgG antibodies were purchased from E-Y Laboratories (San Mateo, CA). Affinitypurified goat anti-rabbit IgG antibodies were purchased from Cappel Laboratories (Cochranville, PA). gp7O, p30, and its polyprotein precursor p65 were detected with anti-gp7O and anti-p30 antiserum, respectively. These NIH reference sera were prepared by immunization of goats with the envelope and core proteins from the Rauscher strain of MuLV and were supplied by Hazelton Research Primates (Reston, VA). Anti-p30 was reference antiserum 5123, and anti-gp70 was reference antiserum 5129. An interspecies anti-p30 was also used and was a generous gift from Tom Kawakami of this institution. This antiserum was received originally from R. V. Gilden (National Cancer Institute).
Radioiodination of Antibodies. Radioiodinated antibodies were prepared by the chloramine-T method (18) . Between 0.5 and 1.5 mg of affinity-purified antibodies in 200 ,ul of Pi/NaCl was mixed with 2.0 mCi (1 Ci = 37 GBq) of carrierfree Na125I (Amersham) in a glass culture tube. The reaction was initiated by the addition of 20 ,l of chloramine-T (2.4 mg/ml in P,/NaCI) and terminated after 1.5 min by the addition of 100 ,l of potassium metabisulfite (2.4 mg/ml in Pi/ NaCl). The reaction mixture was immediately placed on a 5ml column of Sephadex G-25 and eluted with Pi/NaCl. The 5) and its EBV-converted subline AW-Ramos (lanes 1, 3, 4, and 6 ). Ninety micrograms of Triton X-100-soluble protein was loaded per lane. After electrophoresis, proteins were electroblotted onto nitrocellulose. Lanes 1-3 were incubated with rabbit immune antiserum against AW-Ramos cells. Lanes 4-6 were incubated with preimmune rabbit serum. Antigen-antibody complexes were visualized using 1251-labeled goat antibodies to rabbit IgG and autoradiography was done as described.
Protein Assay. The Coomassie blue G-250 binding assay of Bradford (19) was used to determine protein concentration. Bovine serum albumin was used as a standard.
Proc. NatL Acad Sci USA 81 (19841 35 BJAB/B-1 and BJAB/B95-8. This figure compares immunoblots of plasma-membrane-enriched proteins using antiserum to AW-Ramos. In this experiment, membrane proteins derived from Ramos (lane 1) and two EBV-converted derivatives, AW-Ramos and Ramos/B95-8 (lanes 2 and 3), were compared with BJAB (lane 4) and two of its EBV-converted sublines (lanes 5 and 6). In confirmation of the results shown in Fig. 1, a major difference between the two EBV-converted Ramos lines and their EBV-negative parent was an increased expression of p32 in the converted lines (lanes 2 and 3) . In contrast, p32 was not expressed in BJAB or its EBV-converted lines (lanes 4-6), implying that p32 is a protein not directly related to the presence of the EBV genome. A second major difference between Ramos and BJAB was the appearance of p65 in the Ramos lines. Like p32, the amount of this protein was increased in the Ramos-converted lines and was completely absent in BJAB and its EBV-converted derivatives. These findings show an enhanced expression of proteins in the 30-and 65-kDa region in the Ramos-converted lines but not BJAB, suggesting that EBV conversion of Ramos resulted in an amplification of the MuLV provirus that was present in Ramos but not in BJAB. The 32-kDA protein would thus correspond to the MuLV gag gene protein p30, and the 65-kDa protein to the p30 polyprotein precursor p65. This supposition was confirmed as described below. Confirmation that the rabbit antiserum detected immunoreactive proteins unique to the presence of EBV (Fig. 1) is also shown in Fig. 2 . Proteins in the Mr range 72,000-85,000 were present in the EBV-converted BJAB lines but not in BJAB (lanes 4-6). Proteins of similar Mr also show immunoreactivity with human EBV-seropositive but not -seronegative antiserum, indicating that these proteins may be nuclear antigens (results not shown). Identification of gag Gene Protein p30 in Ramos Lines. The 32-kDa antigen was identified as the retroviral gag gene product p30 by immunoblotting analysis with an antibody specific for retroviral p30. In this experiment (Fig. 3 ) a NIH reference antiserum specific for gag p30 from the Rauscher 
RESULTS
Identiflcation of Antigenic Components Using Rabbit Antisera to EBV-Converted Cells. Fig. 1 shows an immunoblot of Triton X-100-solubilized proteins from Ramos (lanes 2 and 5) and one of its EBV-converted sublines, AW-Ramos (lanes 1, 3, 4, and 6). Lanes 1-3 were incubated with rabbit immune antiserum to AW-Ramos; lanes 4-6 represent the same samples incubated with preimmune rabbit serum. As expected, many of the proteins recognized by the immune antiserum are common to both the EBV-negative and converted cell lines. There are, however, a number of qualitative and quantitative differences that can be seen between the EBV-negative and converted lines. In AW-Ramos, for example, the enhancement of proteins at 63 and 61 kilodaltons (kDa) and the diminution of proteins at 45 and 36 kDa appear to be related to the presence of the EBV genome. Such an antigen(s) may be the target of EBV-specific immunosurveillance. For the purpose of this study, however, it is relevant to note the increased amount of proteins with apparent Mrs in the presence of NaDodSO4 of 32,000 (p32) and 65,000 (p65) in the AW-Ramos converted line, compared to Ramos.
To determine whether the results shown in Fig. 1 were reproducibly related to the presence of the EBV-genome and not merely reflective of clonal or harvest differences, similar analysis were carried out on several independent harvests of EBV-negative and converted lines. The experiment shown in Fig. 2 Fig. 3 confirm the identity of the 32-kDa antigen as retroviral p30 and the 65to 67-kDa protein as p65, the polyprotein precursor for p30. These results also confirm that EBV conversion of Ramos enhances the expression of p30 and p65 in all three of the Ramos-converted lines. No retroviral reactivity is seen in BJAB or in its converted line (lanes 5 and 6).
A second independent confirmation of p30 and p65 amplification in the EBV-converted Ramos lines was provided by immunoblotting with an interspecies p30 antibody that crossreacts with all mammalian retroviral p30 (results not shown).
Quantitation of p30 Expression. EBV amplification of p30 was quantitated by measuring the amount of iodinated second antibody bound to the specific anti-p30/p30 immune complex. In Fig. 4 , the amount of labeled antibody was plotted as a function of the amount of total protein loaded on the gel. As shown, this procedure was linear over the range of 22 to 270 tzg of membrane protein loaded in each lane. The lower line shows the amount of p30 that was expressed constitutively in Ramos; the upper line shows the increased level of p30 in AW-Ramos. The difference between these two lines showed that p30 expression was amplified 3-to 5-fold in AW-Ramos. Immunoblotting analysis with goat anti-p30 antiserum was carried out as described. The areas on the nitrocellulose blot containing p30 reactivity in each lane were cut out. The radioactivity of "251-labeled rabbit antibodies to goat IgG in each slice was determined. The dpm for each slice is shown as a function of the amount of protein loaded onto the gel in that lane. p30, was expressed constitutively at low levels in Ramos and increased in all three EBV-converted Ramos lines. Quantitative analysis showed that retroviral gp7O expression was also enhanced ca. 3to 5-fold in the EBV-converted lines (results not shown). In confirmation of the gag gene p30 results, gp7O also was not expressed in BJAB and its converted line.
DISCUSSION
These studies have shown that the EBV-negative BL line Ramos, but not BJAB, expresses constitutively at low levels the MuLV proviral genome. These results are based on im- munoblotting experiments using antisera to the specific MuLV gene products, p30 and gp70.
Both qualitative and quantitative evidence has shown that EBV conversion of Ramos amplifies expression of the MuLV provirus 3-to 5-fold. Amplification is not simply the result of a nonspecific stimulation of protein synthesis by the EBV genome because, as shown in Fig. 1 , many of the proteins recognized by the imhmune antiserum (lanes 1-3) are present in identical amounts. Thus, p30 and p65 are two of only a few of the proteins increased in the EBV-converted line that are recognized by the rabbit antiserum. Because identical amounts of protein were loaded into each well (Fig.  1-3 and 5 ), the increase in retroviral reactivity clearly appears to be related to only a few specific proteins. The fact that expression of both p30 and gp70 antigens are enhanced in the converted Ramos lines suggests that the entire MuLV genome is amplified. No evidence is presented, however, concerning the expression of the MuLV pot gene.
The data presented here confirm an earlier observation by Achong et al. (20) that BL tumors grown in nude mice contain C-type retroviral particles. When the Ramos cell line was established from an EBV-negative American BL, the cells were passaged through nude mice (6) . Presumably, it was during these passages that Ramos acquired the MuLV provirus. The EBV-negative line BJAB was not passaged in nude mice and consequently does not express MuLV antigens (12) .
The mechanism of EBV enhancement of MuLV gene expression is not known. Whether insertional activation is directly responsible for the enhanced expression remains to be determined. Our rationale is based on the mechanism of MuLV activation of cellular onc genes, which may be relevant. The 5' long-terminal repeats of the MuLV provirus have been shown to contain a hypothetical promoter site for transcription (21) . Hayward et at. (22) have shown that the avian leukosis virus 5' long-terminal repeat region nearly always inserts adjacent to a cellular onc sequence in avian leukosis virus-induced lymphomas. The long-terminal repeat sequence thus acts as a promoter for the transcription of the cellular onc genes. The termini of EBV DNA contain repeated sequences (23) . EBV DNA also contains internal repeat sequences that include putative promoter sequences (24) . If the appropriate promoter region in the EBV genome integrated adjacent to an endogenous MuLV genome, this may have resulted in increased expression of MuLV gene products. Thus, MuLV activation by EBV may involve downstream promotion and transcriptional activation of the amplified genes. In addition, enhancer sequences have been identified in various retroviruses, simian virus 40, papovavirus, and polyoma virus (25) . These enhancer sequences increase the rate of transcription irrespective of orientation and distance. Investigations at the level of direct DNA interaction will determine whether insertion of promoter or enhancer regions of EBV is occurring.
Amplification of viral MuLV DNA could also occur by viral production followed by reinsertion of new copies of viral DNA. Enhancement of this process by the presence of the EBV genome is an alternative mechanism for EBV-induced amplification. Present results do show, however, that increased MuLV copy number and MuLV demethylation are not involved (unpublished results).
Although the biological relevance of the possible interaction between a DNA and RNA tumor virus is unclear, amplification of MuLV provirus by EBV may have important implications regarding the mechanism of tumor induction by retroviruses. Recent studies have shown that normal human DNA contains at least one copy of a retroviral onc-gene analogue that is transcribed constitutively and that this expression is enhanced in several human tumors (26) . Results of the present studies suggest, although they do not prove, that one mechanism of activating cellular oncogenes in human B-lymphoid cells may be by interaction with a ubiquitous DNA virus.
Finally, the results of these studies show that caution must be exercised when describing antigenic determinants as being unique to EBV. This is particularly important when working with Ramos and its converted lines. In this case, it is essential to verify that the unique antigens are not in fact retroviral proteins or their polyprotein precursors. This warning also extends to the use of these cells as immunogenes, for as the results in Figs. 1 and 2 show, immunization of rabbits with whole cells elicited antibodies that recognized proteins of the same Mr as the retroviral antigens.
